LFB in the world

Today, LFB markets biomedicinal products in around a dozen European countries, with the support of its subsidiaries and commercial partners.

EUROPLASMA, a subsidiary of LFB, manages 26 plasma and blood collection centres in Europe:

• 5 centres in the Czech Republic,
• 9 centres in Austria,
• 2 centres in Germany.

LFB is thus committed to increasing its plasma collection capacity in order to meet the growing demand from patients in Europe. Securing a continuous supply of plasma is a major public health issue.

Blood products, including plasma, are collected in France by a single operator: the “Etablissement Français du Sang” (EFS).
In France, donations of plasma, blood and platelets are voluntary, anonymous, unpaid and uncompensated.

Thanks to its CDMO status (Contract Development and Manufacturing Organization), and approved by the FDA (Food and Drug Administration), the Alès site shares its know-how and equipment with its customers, including support from the development of cell lines and industrial-scale processes to the manufacture of clinical and commercial batches, as well as the associated analytical testing. It is one of LFB’s key entities specialising in the bioproduction of therapeutic proteins, in particular monoclonal antibodies, by cell culture.

The Arras site is a new generation plant that houses all of the production steps for 3 medicinal products.
Commissioned at the end of 2024, this plant will enable LFB to triple its production capacity.
With this € 750 million investment, LFB will make a real technological leap forward

The Carvin site (Pas-de-Calais department, France) offers a warehouse to store the materials needed to produce medicinal products for the Lille plant.
It is also the packaging site for LFB’s liquid products.

The Lille plant (North department, France) specialises in the downstream steps of the production processes for plasma-derived medicinal products, from the intermediate products to aseptic filling.

The Les Ulis plant (Essonne department, France) specialises in the upstream steps of the production processes for plasma-derived medicinal products, from receipt of the bags of plasma to the intermediate products.
LFB’s head offices are located in Paris.

LFB and its American subsidiary LFB Plasma manage 6 plasma collection centres in the United States of America: in Alabama, Colorado, Florida, North Carolina and South Carolina.

In accordance with US FDA requirements, “Food and Drug Administration”, only medicinal products derived from plasma donated in the USA can be sold in the USA.

LFB markets a plasma-derived medicinal product in the United States of America.
LFB is also present in Mexico, through its subsidiary LFB MEXICO responsible for the marketing of several plasma-derived medicinal products, and in Colombia.

LFB also markets its products in some countries in the rest of the world through commercial partners.